Organigram Global (OGI) Stock Price, News & Analysis

Company Overview

Organigram Global Inc. (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts. Organigram distributes under a variety of brands, including Monjour, Edison and First Growth, targeting diverse consumer segments from value-focused to premium. Its cultivation methods combine indoor and greenhouse systems with automated processes designed to ensure product consistency, safety and quality.

Organigram serves markets across Canada and has established partnerships to access select international markets in jurisdictions that recognize Canadian GMP certification. The company’s leadership team is led by Chief Executive Officer Greg Engel, who has guided Organigram through its public listings on the Toronto Stock Exchange and the Nasdaq in 2020. Under his management, Organigram has focused on innovation in product formats, efficiency in cultivation, and strategic brand development to navigate the evolving regulatory landscape.

Key Stats

• Today's Range: $1.97 to $2.08
• 50-Day Range: $1.33 to $2.03
• 52-Week Range: $0.85 to $2.08
• Volume: 977,979 shs
• Average Volume: 881,114 shs
• Market Capitalization: $271.37 million
• P/E Ratio: 40.41
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Organigram Global Stock Analysis - MarketRank™

Organigram Global scored higher than 23% of companies evaluated by MarketBeat, and ranked 890th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Organigram Global.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Organigram Global are expected to grow in the coming year, from ($0.19) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram Global is 40.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram Global is 40.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.94.

Price to Book Value per Share Ratio

Organigram Global has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.82% of the float of Organigram Global has been sold short.

Short Interest Ratio / Days to Cover

Organigram Global has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Organigram Global has recently decreased by 0.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram Global does not currently pay a dividend.

Dividend Growth

Organigram Global does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.82% of the float of Organigram Global has been sold short.

Short Interest Ratio / Days to Cover

Organigram Global has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Organigram Global has recently decreased by 0.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

Organigram Global has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Organigram Global this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

7 people have added Organigram Global to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organigram Global insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.09% of the stock of Organigram Global is held by insiders.

Percentage Held by Institutions

Only 34.63% of the stock of Organigram Global is held by institutions.

OGI Stock Analysis - Frequently Asked Questions

How have OGI shares performed this year?

Organigram Global's stock was trading at $1.61 at the start of the year. Since then, OGI shares have increased by 25.5% and is now trading at $2.02.

How were Organigram Global's earnings last quarter?

Organigram Global Inc. (NASDAQ:OGI) announced its earnings results on Wednesday, August, 13th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.02. The company earned $50.49 million during the quarter, compared to analyst estimates of $68.04 million. Organigram Global had a net margin of 2.86% and a negative trailing twelve-month return on equity of 8.19%.
Read the conference call transcript.

When did Organigram Global's stock split?

Organigram Global's stock reverse split on the morning of Friday, July 7th 2023.The 1-4 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

How do I buy shares of Organigram Global?

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organigram Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram Global investors own include i3 Verticals (IIIV), Ford Motor (F), Lucid Group (LCID), Trade Desk (TTD), Finance of America Companies (FOA), NVIDIA (NVDA) and

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 12/17/2025
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OGI
• CIK: 1620737
• Web: www.organigram.ca
• Phone: (844) 644-4726
• Fax: N/A
• Employees: 860
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 40.41
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.39 million
• Net Margins: 2.86%
• Pretax Margin: -1.50%
• Return on Equity: -8.19%
• Return on Assets: -5.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.59
• Quick Ratio: 1.42

Sales & Book Value

• Annual Sales: $117.47 million
• Price / Sales: 2.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 134,340,000
• Free Float: 134,221,000
• Market Cap: $271.37 million
• Optionable: Optionable
• Beta: 1.48